Biotech stocks are trading down this year, taking a beating after Robert F. Kennedy Jr. was confirmed as the secretary of the Department of Health and Human Services.
↑
X
CRSP Stock On Wild Ride After FDA’s Historic Approval. These Gene Editing Treatments Could Come Next.
Kennedy is a well-known vaccine skeptic. In February, the Food and Drug Administration — one of the agencies under the HHS umbrella — unexpectedly canceled the annual meeting to select the strains targeted by this year’s suite of flu shots. Reports also emerged that HHS is considering pulling the $590 million in federal funds granted to Moderna (MRNA) to develop a bird flu vaccine.
But Kennedy, or RFK Jr., is also open to the use of psychedelics in therapeutic settings. But even shares of biotech companies working in that space have struggled recently.
On a year-to-date basis, the biotech industry group has fallen about 5% as of midday trades on March 7. The 727-company industry group ranks No. 66 out of 197 groups Investor’s Business Daily tracks. Further, the Relative Strength Rating of 68 — a measure of 12-month performance against all other groups — has fallen from 97 just a year ago.
But it’s key to watch specific measures when examining stocks. In terms of fundamental and technical metrics, some biotech stocks are showing strength. The best biotech stocks trading above 10 right now are:
- Halozyme Therapeutics (HALO)
- Exelixis (EXEL)
- Catalyst Pharmaceuticals (CPRX)
- Alkermes (ALKS)
- GeneDx (WGS)
This Biotech Stock Gets Under Your Skin
Halozyme Therapeutics is an expert in drug delivery.
The company is known for its Enhanze technology, which helps deliver drugs under the skin via a subcutaneous injection.
The technology is behind some of the biggest drugs including Johnson & Johnson‘s (JNJ) Darzalex Faspro and Roche‘s (RHHBY) Herceptin. Both are cancer treatments. Halozyme also won approval for a subcutaneous form of Roche’s multiple sclerosis drug. It’s selling under the name Ocrevus Zunovo.
Recently Halozyme reported adjusted earnings of $1.26 per share on $298 million in sales for the fourth quarter. Both measures topped forecasts, with earnings growing almost 54% and sales climbing nearly 30%. For 2025, Halozyme expects $1.15 billion to $1.225 billion in sales, up 13% to 21%. The company also guided to 17% to 26% adjusted profit growth.
Halozyme stock has a strong Composite Rating of 98, and a Relative Strength Rating of 92.
Shares are consolidating with an entry at 65.53, and remain above their 50-day and 200-day lines, according to MarketSurge.
Halozyme also lands on the IBD Tech Leaders list.
Exelixis Focuses On Cancer Drugs
Exelixis is a relatively new addition to the list of top biotech stocks. The company has made a name for itself as a cancer treatment specialist. It sells Cabometyx, a treatment for several forms of kidney, liver and thyroid cancer. The company’s Cometriq treats thyroid cancer.
In the December quarter, Exelixis earned 55 cents per share, minus some items, on $567 million in sales. Earnings beat forecasts by a dime per share and grew about 67% year over year. Sales rose more than 18% and topped projections for $564 million.
The company also guided to $2.15 billion to $2.25 billion in sales for 2025. That includes $1.95 billion to $2.05 billion in sales of its products.
The biotech stock is above its 50-day and 200-day lines. Shares have a Composite Rating of 98 and a lower RS Rating of 96.
The biotech stock lands on the Tech Leaders list as well. Notably, Exelixis shares rank No. 19 on the IBD 50 list of elite growth stocks.
Highly Rated Catalyst Stock
Catalyst Pharmaceuticals licenses approved or soon-to-be approved treatments for rare diseases and diseases of the central nervous system.
Today, the company has three products. Firdapse treats a neuromuscular condition that often affects small cell lung cancer patients. Fycompa is a seizure treatment. Catalyst also has a Duchenne muscular dystrophy drug called Agamree.
In January, Catalyst struck a deal with Teva Pharmaceutical (TEVA) that will prevent the drugmaker from launching a generic version of Firdapse until 2035.
During the fourth quarter, Catalyst earned 70 cents per share, minus some items, and reported $141.8 million in sales. Both metrics easily topped analysts’ forecasts. Earnings surged 32% and sales rose about 30%. This year, Catalyst expects $545 million to $565 million in sales.
The biotech stock is trading just below its 50-day moving average, but remains above its 200-day line. Shares broke out of a consolidation with a buy point at 24.27 on Jan. 30. But Catalyst stock later fell as much as 10.5% below that entry, triggering a sell rule. Savvy investors are encouraged to cut their losses when a stock falls 7% to 8% below its entry.
Catalyst stock has a strong Composite Rating of 98 and a Relative Strength Rating of 88.
Catalyst stock is also an IBD Tech Leader.
Alkermes Returns As A Top Biotech
Alkermes is well known for its neuroscience focus. The company makes Lybalvi, a treatment for bipolar one and schizophrenia. It also has another schizophrenia drug called Aristada and Vivitrol, a treatment for alcohol dependence.
In the fourth quarter, Lybalvi sales climbed 37% to $77 million. Aristada sales were bigger at $96.6 million, but grew a less bullish 16%. Vivitrol sales surged 31% to $134.1 million. Lybalvi sales came up short, while Aristada and Vivitrol sales beat forecasts.
Shares surged about 7.5% on Feb. 13, the day after Alkermes reported its fourth-quarter earnings.
The biotech stock broke out of a lengthy cup-with-handle base with a buy point at 32.25 on Feb. 12. Shares are now just above the 5% buy zone.
Shares have a Composite Rating of 96, but a lower Relative Strength Rating of 92.
Alkermes shares rank No. 30 on the IBD 50.
GeneDx Makes Its Way Back
GeneDx has returned to the list of top-notch biotech stocks.
The company makes sequencing tests that scan a person’s exome or genome. The exome accounts for all protein-coding genes within a person’s DNA, while the genome accounts for all genes, regardless whether they code for proteins.
During the fourth quarter, GeneDx earned an adjusted 77 cents per share on $95.6 million in sales. Earnings flipped from a year-earlier loss, while sales climbed almost 65%.
The biotech stock rocketed nearly 48% on Feb. 18 after GeneDx announced a rapid test to deliver results in as soon as 48 hours to help critically ill newborns and children in a hospitals’ intensive care units.
Shares are on the rise with a perfect Relative Strength Rating of 99 and a strong Composite Rating of 98.
The biotech stock ranks No. 17 on the IBD 50.
Follow Allison Gatlin on X/Twitter at @AGatlin_IBD.
YOU MAY ALSO LIKE:
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Eli Lilly Has A Big Stake In Weight Loss And Alzheimer’s Drugs; But Is The Stock A Buy?
Get Timely Buy & Sell Alerts With IBD Leaderboard
Want More IBD Insights? Subscribe To Our Investing Podcast!
Options Trading: How To Start Using Options; How To Manage Risk
